CORRECTED - CORRECTED-BRIEF-Wyeth, Catalyst Biosciences sign agreement

(Corrects company name in the headline to Catalyst, not Satalyst)

June 30 (Reuters) - Wyeth WYE.N: * Wyeth Pharmaceuticals and Catalyst Biosciences announce agreement to develop and commercialize factor VIIa products * Says total payments under the collaboration, including an upfront payment of $21 million * Says total payments under the collaboration could exceed $500 million, exclusive of royalty payments * Catalyst Biosciences says it would earn payments of up to $40 million or more over the next two years * Says term of the exclusive research portion of the collaboration is two years * Says term may be extended by Wyeth for up to three additional years * Says during the research term of the agreement, Catalyst will receive support for up to 12 full-time employees